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Type 1 diabetes is a T cell-mediated autoimmune
disease, characterized by lymphocytic infiltration of
the pancreatic islets. It is currently thought that islet
antigen specificity is not a requirement for islet entry
and that diabetogenic T cells can recruit a heteroge-
neous bystander T cell population. We tested this
assumption directly by generating T cell receptor
(TCR) retrogenic mice expressing two different T cell
populations. By combining diabetogenic and nondia-
betogenic or nonautoantigen-specific T cells, we
demonstrate thatbystanderTcells cannot accumulate
in the pancreatic islets. Autoantigen-specific T cells
that accumulate in islets, but do not cause diabetes,
were also unaffected by the presence of diabetogenic
T cells. Additionally, 67%of TCRs cloned fromnonob-
ese diabetic (NOD) islet-infiltrating CD4+ T cells were
able to mediate cell-autonomous islet infiltration and/
or diabeteswhenexpressed in retrogenicmice. There-
fore, islet entry and accumulation appears to be a
cell-autonomous and tightly regulated event and is
governed by islet antigen specificity.
INTRODUCTION
Juvenile type 1 diabetes (T1D) is a T cell-mediated autoimmune
disease, characterized by progressive lymphocytic infiltration of
the pancreatic islets. This insulitis ultimately leads to the destruc-
tion of the insulin-producing b cells, resulting in diabetes. As with
most autoimmune diseases, patients present once the disease
has progressed for some time. This inevitably makes study of
early events in the disease, such as T cell islet entry and accumu-
lation, difficult. However, the NOD mouse model closely mimics
the human disease, with approximately 80% of female NOD
mice developing diabetes spontaneously between 12 and 22
weeks of age (Delovitch and Singh, 1997). In addition, the
disease is T cell mediated with both CD4+ and CD8+ T cells
contributing to b cell destruction (Delovitch and Singh, 1997).
A large number of putative autoantigens have been proposed,
including insulin, glutamic acid decarboxylase (GAD) 65, IGRP,
IA-2, and IA-2b (Phogrin), on the basis of autoantibody detectionand the isolation of autoantigen-specific T cell clones (Lieber-
man and DiLorenzo, 2003). In addition, a number of T cell clones
of unknown antigen specificity have been identified that prolif-
erate in response to whole islets and can cause disease when
adoptively transferred into mice (Haskins, 2005). Of these,
TCRs from BDC2.5, BDC6.9, and NY4.1 have been used to
generate NOD transgenic mice that exhibit accelerated diabetes
(Gonzalez et al., 1997; Pauza et al., 2004; Schmidt et al., 1997).
There is a widely held, but largely unsubstantiated, theory that
the insulitis seen in NOD mice and T1D patients is initiated by
diabetogenic T cells that then recruit a heterogeneous mixture
of cells that includes bystander T cells that are not autoantigen
specific and might not contribute to disease. Thus, it is perceived
that such diseased islets are ‘‘leaky’’ and that only a proportion of
accumulating T cells is actually responsible for b cell destruction.
However, direct support for this notion is very limited, and in part
conflicting. Although a heterogeneous population of T cells is
recruited to the islets of 2-week-old NOD mice after adoptive
transfer of BDC2.5 or BDC6.9 T cell clones (Peterson et al.,
1998), all of the infiltrating polyclonal cells may be insulitogenic
on their own. Two GAD-specific CD4+ T cell clones, generated
from human HLA transgenic mice, were shown to induce insulitis
in recipient mice but only after treatment with low-dose strepto-
zotocin (Wen et al., 1998). It was suggested that this treatment
causes damage to the islets, providing an inflammatory environ-
ment that attracts T cells to the islet. In a virus-induced model of
diabetes, expression of the chemokine CXCL10 alone in the
islets is sufficient to cause peri-insulitis but not b cell destruction
(Rhode et al., 2005). Conversely, a neutralizing CCR5 antibody,
which blocks the action of CCL5 expressed by pancreatic islets,
does not alter peri-infiltration in the pancreas of NOD mice, but it
does inhibit b cell destruction and diabetes (Carvalho-Pinto
et al., 2004). Several studies have suggested that T helper 1
(Th1) cells are responsible for aggressive disease, whereas Th2
cells infiltrate more slowly and do not induce diabetes (Hill
et al., 2003). It was inferred that the inflammation generated by
Th1 cells might attract T cells that would not normally accumu-
late in the islets. Thus it is still not clear whether the ability of
T cells to home to or be retained in the islets is cell autonomous,
because of their antigen specificity or expression of chemokine
receptors, or whether this is induced directly or indirectly by
autoantigen-specific diabetogenic T cells (Sercarz, 2000).
Our laboratory has previously used 2A-linked peptide-based,
multicistronic retroviral vectors containing both chains of theImmunity 31, 643–653, October 16, 2009 ª2009 Elsevier Inc. 643
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Control of T Cell Islet AccumulationT cell receptor to efficiently reconstitute NOD-SCID mice with
T cells bearing a defined receptor (referred to as ‘‘retrogenic’’
mice; see Figure S1A available online; Arnold et al., 2004; Holst
et al., 2006a, 2006b; Burton et al., 2008). We have used this
system to investigate the expression, infiltration, and diabetoge-
nicity of a variety of T cell populations. Our findings suggest that
although some autoantigen-specific T cells can enter and accu-
mulate in the islet, they do not appear to cause destruction.
Also, some T cells, which are antigen responsive in vitro, do not
infiltrate in vivo (Arnold et al., 2004; Burton et al., 2008). This
implies that the ability to enter and accumulate in the islets (insu-
litogenic potential) and the ability to destroy the b cells and cause
diabetes (diabetogenic potential) may be separate. In this study,
we used this system to generate double retrogenic mice, contain-
ing two distinct T cell populations, to ask whether diabetogenic
T cells can indeed mediate the recruitment of bystander T cells,
or whether T cell islet entry and accumulation is an antigen-
specific, cell-autonomous event.
RESULTS
Presence of Diabetogenic CD4+ T Cells Does Not
Facilitate Islet Accumulation of Bystander CD4+ T Cells
We have previously used our 2A-linked retroviral vectors to
generate retrogenic mice (Figure S1A) expressing a variety of
T cell receptors, specific for various antigens, and with varying
abilities to infiltrate the pancreatic islets and cause diabetes
(Arnold et al., 2004; Burton et al., 2008). Here we created double
retrogenic mice by combining two groups of bone marrow, each
expressing a different TCR, and then transplanting them into
sublethally irradiated NOD-SCID mice (Figure S1B; Holst et al.,
2006a, 2006b). By incorporating either GFP or YFP into the
vectors, we were able to distinguish the two T cell populations
after engraftment even if they used the same Vb chain.
Initially, we investigated whether a bystander T cell, specific
for an antigen not present in the islet, could gain entry to the islet
and accumulate in the presence of a diabetogenic T cell (Figure 1;
Figures S2 and S3). To do this, we used NY4.1 (4.1) and BDC2.5,
two diabetogenic CD4+ T cells of unknown antigenic specificity,
with PA21.14H4 (14H4) and PA21.5F2 (5F2), two hen egg lyso-
zyme (HEL)-specific CD4+ T cells, as bystander T cells (Table
S1). When 4.1 T cells were combined with either 14H4 or 5F2
T cells, both populations were comparably expressed in the
spleen (Figure S2). When BDC2.5 was combined with 14H4,
however, the BDC2.5 T cells were expressed in much lower
numbers than the 14H4, despite both vectors being comparably
expressed in the LineageSca-1+c-Kit+ stem cells of the bone
marrow (Figure S3). In mice expressing 4.1 with either 14H4 or
5F2, the pattern in the inguinal lymph nodes mirrored that seen
in the spleen (Figure S2). However, there appeared to be
a much larger percentage of diabetogenic 4.1 T cells in the
pancreatic lymph nodes, compared to the bystander cells
(Figure S2). In the pancreatic islets, little or no HEL-responsive
5F2 or 14H4 T cells were observed, regardless of the diabeto-
genic T cell used (Figures S2 and S3), which was comparable
to 5F2 or 14H4 T cells expressed alone (Figure S2).
Given that the double retrogenic mice received twice as much
bone marrow as the single retrogenic mice, we also wanted to
rule out the possibility that this might affect reconstitution. To644 Immunity 31, 643–653, October 16, 2009 ª2009 Elsevier Inc.address this issue, we combined 4.1-bone marrow with an equal
amount of bone marrow that had been transduced with an empty
vector to confirm that transplanting twice as much total bone
marrow to generate double, compared to the single, retrogenic
mice did not affect reconstitution. As can be seen, the numbers
of 4.1 T cells in all organs were identical between the two groups,
suggesting there was no adverse consequence of only trans-
planting half as much bone marrow on T cell development and
islet infiltration (Figure 1B).
Islet Entry or Accumulation Is Independent of the Ratio
of Diabetogenic to Bystander CD4+ T Cells
Next, we investigated whether increasing the number of
bystander T cells would allow them to enter. To address this
issue, we skewed the ratio of diabetogenic and bystander TCR-
transduced bone marrow transplanted to increase the splenic
14H4 bystander population and determine whether this would
increase infiltration of the bystander T cells or effect the infiltration
of the diabetogenic 4.1 T cells (Figures 1A and 1B). Transplanting
a 10:90 (4.1:14H4) mix of the two bone marrow populations did
indeed result in a marked reduction in the percentage of YFP+
(4.1) and an increase in percentage of GFP+ (14H4) Linea-
geSca-1+c-Kit+ hematopoietic stem cells (HSCs) in the bone
marrow, compared to the mice receiving a 50:50 ratio of the
two bone marrows (Figure 1B). A similar skewing was observed
in the spleen and inguinal lymph nodes, with reduced numbers
of 4.1 T cells, compared to the single retrogenic control and the
50:50 mix. 14H4 T cell numbers in the spleen were similar to the
single retrogenic control and larger than the 50:50 mix (Figure 1B).
Although the numbers of 14H4 cells in the distal inguinal lymph
nodes were reduced compared to a single retrogenic control,
the ratio of the two TCRs remained similar to the spleen. In the
pancreatic lymph nodes, an increase in 14H4 T cells was not
seen but there was a marked reduction in the numbers of 4.1
T cells such that the 14H4:4.1 ratio was similar in all lymph nodes
examined. This skewing toward 14H4 and away from 4.1 did not
have any effect on the populations accumulating in the pancreatic
islets. Similar numbers of islet-antigen-responsive 4.1 T cells
were recovered from the islets of all four groups receiving 4.1-
transduced bone marrow, and no substantial accumulation of
HEL-responsive 14H4 T cells was observed in any group, regard-
less of how many were present in the spleen and lymph nodes
(Figures 1A and 1B). Thus, these data suggest that islet entry or
accumulation is independent of the ratio of diabetogenic to
bystander CD4+ T cells and that the former may not be able to
induce the islet entry or retention of the latter.
A Heterogeneous NOD Diabetogenic T Cell Population
Cannot Facilitate Bystander CD4+ T Cell Islet
Accumulation
We then considered the possibility that our diabetogenic T cells,
BDC2.5 and 4.1, were unusual in being unable to mediate
bystander accumulation or that this is most efficiently facilitated
in the presence of a ‘‘natural’’ cohort of diabetogenic T cells such
as those found in NOD mice. To test this, we generated retro-
genic mice by using the HEL-specific PA21.14H4 TCR, which
cannot accumulate in the islet, and adoptively transferred 107
whole NOD splenocytes from 13-week-old mice, 2 weeks after
bone marrow engraftment. Although the percentage of GFP+
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Figure 1. HEL-Specific ‘‘Bystander’’ CD4+ T Cells Do Not Accumulate in the Pancreas
Double retrogenic mice, with a diabetogenic T cell labeled with YFP and a HEL-specific ‘‘bystander’’ T cell labeled with GFP. Mice were analyzed 4.5–6.5 weeks
after transfer, with the bone marrow, spleen, inguinal lymph nodes, pancreatic lymph nodes, and pancreatic islets being extracted and processed, and cells
counted and subjected to flow cytometric analysis.
(A) Representative flow cytometric dot plots from (B), gated on live and CD4+ T cells.
(B) Mice received bone marrow transduced with either 4.1 or 14H4, or both, at a 50:50 ratio, or a 10:90 ratio. One group received 4.1-YFP bone marrow and bone
marrow transduced with empty pMIG vector as a control. Top: mean (±SEM) percentage of stem cells for each T cell in the bone marrow, as measured by
percentage GFP or YFP expression on LineageSca-1+c-kit+ cells (n = 10). Middle and bottom: mean (±SEM) numbers of each T cell in the spleen (n = 9–10),
inguinal lymph nodes (I.L.N., n = 7–9), pancreatic lymph nodes (P.L.N., n = 6–9), and pancreatic islets (Islets, n = 10), respectively, as calculated from cell counts
and the percentage CD4+FP+ live cells.
(C) Representative flow cytometric dot plots from (D), showing analysis of T cells from 14H4 HEL-specific mice, injected with 10 3 106 whole splenocytes from
13-week-old NOD mice, 2 weeks after bone marrow engraftment, and analyzed 4.5–6.5 weeks after transplant. Plots are gated on live cells and CD4+ cells.
(D) Left, percentage of stem cells for each T cell in the bone marrow (n = 7–10), as measured by percentage GFP expression on LineageSca-1+c-kit+ cells and
total numbers of T cells in the spleen. Right panels show the numbers and ratio to the numbers in the spleen for the pancreatic islets (Islets) and pancreatic lymph
nodes (P.L.N.), respectively (n = 5–9). All figures show mean (±SEM) and numbers were calculated from cell counts and the percentage CD4+GFP+Vb+ live cells for
the retrogenic T cells and the percentage CD4+GFPTCR+ live cells for the NOD T cells.HSCs was reduced in the bone marrow of the mice with the addi-
tion of NOD T cells, the numbers of 14H4 cells in the spleen were
comparable to what we see in all other experiments and these
did not significantly (t test, p = 0.2695) differ in the presence ofNOD T cells. Although wild-type NOD splenocytes were able to
infiltrate the islets, the presence of the NOD T cells did not
increase the numbers of 14H4 cells in the pancreatic lymph no-
des or the pancreatic islets, but instead resulted in a slightImmunity 31, 643–653, October 16, 2009 ª2009 Elsevier Inc. 645
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Figure 2. An Autoantigen-Specific CD4+ T Cell that Does Not Accumulate in the Islet Is Increased, but Not to a Significant Extent by the
Presence of a Diabetogenic CD4+ T Cell
Retrogenic mice, with diabetogenic 4.1 T cells labeled with YFP and PA17.9G7 GAD-specific T cells labeled with GFP, were analyzed 5.5 weeks after transplant.
(A) Representative flow cytometric dot plots from (B), showing 4.1 (YFP) and 9G7 (GFP) T cells in the spleen and pancreatic islets. Plots are gated on live cells and
CD4+ cells.
(B) Top: percentage of stem cells for each T cell in the bone marrow, as measured by percentage GFP-YFP expression on LineageSca-1+c-kit+ cells and total
numbers of T cells in the spleen (n = 3–5). Right three panels show numbers and ratio to the numbers in the spleen for the pancreatic islets (Islets, n = 3–5), inguinal
lymph nodes (I.L.N., n = 3–5), and pancreatic lymph nodes (P.L.N., n = 3–5), respectively. All figures show mean (±SEM) and numbers were calculated from cell
counts and the percentage CD4+FP+ live cells.decrease (Figures 1C and 1D). These results indicate that the
presence of a polyclonal NOD T cell population cannot induce
bystander insulitis of non-islet-antigen-reactive 14H4 T cells.
Ectopic Antigen Expression in the Islet Enables
Bystander CD4+ T Cell Islet Entry
If indeed diabetogenic T cells cannot mediate T cell islet entry or
retention, then this should also apply to autoantigen-specific
T cells that do not accumulate in the islets on their own. To verify
this, we determined whether diabetogenic 4.1 T cells could
mediate islet accumulation of CD4+ T cells expressing the
GAD-specific TCR, PA19.9G7, that does not cause insulitis
when expressed in NOD-SCID retrogenic mice (Burton et al.,
2008). The percentage of YFP+ (4.1) and GFP+ (9G7) Linea-
geSca-1+c-Kit+ HSCs in the bone marrow was greatly reduced
when both populations were transferred together, which led to
reduced T cell numbers in the spleen (Figure 2B). However,
both T cell populations were expressed equally and at the
same amount as the single retrogenic mice in the PLN (Fig-
ure 2B). Importantly, the accumulation of 9G7 T cells in the islets
was minimal in both the single and double 4.1+9G7 TCR retro-
genic mice (p = 0.4939) (Figures 2A and 2B).646 Immunity 31, 643–653, October 16, 2009 ª2009 Elsevier Inc.We then used this system to verify that there was no inherent
incapacity of these GAD-reactive CD4+ T cells to enter and accu-
mulate in the islets, by assessing whether cognate antigen
expression in the islets would result in T cell accumulation.
Mouse islets express low levels of GAD65 and GAD67 isoforms
compared to rat and human pancreatic islets (Kim et al., 1993).
We took advantage of the low degree of GAD expression in
murine islets and utilized rip.GAD transgenic NOD-SCID mice,
which strongly express GAD in the pancreatic islets (Bridgett
et al., 1998), and their littermate controls as recipients for the
generation of retrogenic mice. These mice were reconstituted
with NOD-SCID bone marrow transduced with PA17.9G7,
the GAD-specific CD4+ T cell that reacts with GAD284-300, or
PA19.9G11, another GAD-specific CD4+ T cell that reacts with
GAD206-220 (Arnold et al., 2002, 2004). PA21.14H4, the HEL-
responsive T cell, and 10.23, an I-A2-specific T cell that does
not infiltrate the islets to any significant degree, were included
as controls. Both GAD-specific T cells show strong reactivity to
GAD protein but neither infiltrates the pancreatic islets nor
causes diabetes (Arnold et al., 2004). The data clearly show
that both 9G7 and 9G11 T cells enter and accumulate in the islets
of the rip.GAD transgenic mice without further intervention, but
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Figure 3. Expression of an Antigen under the Control of a Rat-Insulin Promoter Allows an Antigen-Specific CD4+ T Cell that Does Not
Normally Accumulate in the Islet to Accumulate
NOD.Cg-Prkdcscid Tg(Ins2-GAD2)2Lt-LtJ transgenic mice and NOD-SCID littermate controls were used as recipients to generate single retrogenic mice, with
either PA21.14H4 ‘‘bystander’’ T cells, 10.23 I-A2-specific T cells, PA17.9G7 GAD-specific T cells, or PA19.9G11 GAD-specific T cells. Mice were analyzed
at 4.5–6.5 weeks after transplant.
(A) Representative flow cytometric dot plots from (B), showing T cells in the spleen and pancreatic islets. Plots are gated on live cells.
(B) Top four panels: mean (±SEM) numbers of each T cell in the spleen, inguinal lymph nodes (I.L.N.), pancreatic lymph nodes (P.L.N.), and pancreatic islets
(Islets), respectively, as calculated from cell counts and the percentage CD4+GFP+ live cells (all n = 1–5). Third panel: mean (±SEM) ratio of CD4+ T cells in
the islets, relative to the numbers in the spleen. Bottom panel: percentage insulitis, at 6.5 weeks after transplant (n = 3–6).do not do so in the nontransgenic littermate controls (Figure 3).
This suggests that antigen expression in the islets is required
for CD4+ T cell islet entry or retention. Furthermore, in situ activa-
tion of autoantigen-specific CD4+ T cells may also be important
because HEL-specific 14H4 T cells do not accumulate in the
islets after in vivo administration of HEL peptide (data not shown).
Diabetogenic CD4+ T Cells Have a Minimal Effect
on the Islet Accumulation of Insulitogenic,
Autoantigen-Specific CD4+ T Cells
It is possible that for diabetogenic T cells to mediate islet accu-
mulation of other T cell populations, the latter must have some
inherent cell-autonomous capacity for islet entry, in which case
the diabetogenic T cells may serve to boost or augment this
process. To test this, we used Phogrin18, a phogrin-specific
CD4+ T cell that enters and accumulates in islets poorly but
reproducibly on its own, and 12-4.4V1, an insulin-specific T cell
that accumulates in the islets freely, is insulitogenic, but does
not cause any diabetes (Burton et al., 2008).The percentages of GFP+ (Phogrin18) LineageSca-1+c-Kit+
HSCs in the bone marrow of the single and double retrogenic
mice were equal (Figure 4B). However, there was a reduced
percentage of YFP+ (4.1) HSCs in the double versus the single ret-
rogenic mice. Development of Phogrin18 T cells was clearly supe-
rior because there were substantially more of these T cells than the
4.1 T cells in the spleen, ILN, and PLN (Figure 4B). These charac-
teristics were duplicated in the 12-4.4V1+4.1 double TCR retro-
genic mice (Figure 5B). If the lymph node data are expressed as
a ratio to the number of T cells in the spleen, then the diabetogenic
(4.1) and nondiabetogenic (Phogrin 18 or 12-4.4V1) T cells were
present in similar proportions, suggesting that none of these
T cells have an enhanced capacity to traffic to a particular lymph
node (Figures 4B and 5B). Although the presence of the 4.1 diabe-
togenic T cells did increase the number of Phogrin18 T cells accu-
mulating in the islets (from 0.397 ± 0.186 to 1.380 ± 0.333 in
the double retrogenic mice [mean 3 104 ± SEM 3 104]; t test,
p = 0.018) (Figure 4B), this increase was still very small compared
to the number of islet-antigen-specific 4.1 T cells in the islets. InImmunity 31, 643–653, October 16, 2009 ª2009 Elsevier Inc. 647
Immunity
Control of T Cell Islet AccumulationIslets
4.1-YFP + 
Phogrin18-GFP
Phogrin18-GFP
4.1-YFP 
Phogrin18-GFP
4.
1 
(Is
le
t A
g)
-Y
FP
Spleen
A
10
0
10
1
10
2
10
3
10
4
88.9 0.37
0.1210.6
85.2 0.11
5.88e-314.7
10
0
10
1
10
2
10
3
10
4
7.47 0.27
89.13.2
74 0.11
22.53.39
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
0 0.16
98.31.54
10
0
10
1
10
2
10
3
10
4
0 0
64.735.3
B
Spleen
0
50
100
150
Spleen
0
10
20
30  4.1 (Islet Ag)-YFP+
 Phogrin18-GFP+
Bone marrowSpleen
10
15
*
0.6
0.8
1.0
Islets
I.L.N.
0
5
10
15
20 I.L.N.
P.L.N.
0.0
0.2
0.4
0.6
0.8
1.0
0
10
20
30
P.L.N.
C
D
4+
FP
+
ce
lls
 x
 1
04
tio
 o
f C
D
4+
FP
+
ce
lls
 to
 s
pl
ee
n
0.0
0.2
0.4
0.6
0.8
1.0
Li
n-
Sc
a-
1+
cK
it+
/F
P+
ce
lls
 (%
)
Islets
Phogrin18
4.1 (Islet Ag) 100 50
100 50
100 50
100 50
0
5
0.0
0.2
0.4
R
at
Figure 4. An Autoantigen-Specific CD4+ T Cell that Accumulates in the Islet Poorly Is Increased, but Not to a Significant Extent by the
Presence of a Diabetogenic CD4+ T Cell
Retrogenic mice, with diabetogenic 4.1 T cells labeled with YFP and Phogrin18 phogrin-specific T cells labeled with GFP, were analyzed 4.5–6.5 weeks after
transplant.
(A) Representative flow cytometric dot plots from (B), showing 4.1 (YFP) and Phogrin18 (GFP) T cells in the spleen and pancreatic islets. Plots are gated on live
cells and CD4+ cells.
(B) Top: percentage of stem cells for each T cell in the bone marrow, as measured by percentage GFP/YFP expression on LineageSca-1+c-kit+ cells and total
numbers of T cells in the spleen (n = 12–15). Next three panels show numbers and ratio to the numbers in the spleen for the pancreatic islets (Islets, n = 12–15),
inguinal lymph nodes (I.L.N., n = 10–15), and pancreatic lymph nodes (P.L.N., n = 10–14). All figures show mean (±SEM) and numbers were calculated from cell
counts and the percentage CD4+FP+ live cells. *p = 0.018, t test.contrast, a substantial number of 12-4.4V1 T cells accumulate in
the islets, albeit to a lesser extent than 4.1 (Figure 5B). However,
they were completely unaffected by the presence of 4.1 diabeto-
genic T cells. We also tested whether a pathogenic CD8+ T cell
can increase recruitment of CD4+ T cells. Islet-antigen-specific,
diabetogenic CD8+ AI4 T cells (DiLorenzo et al., 1998; Chaparro
etal., 2008) did not increase infiltration of 10.23 CD4+ T cells,which
suggests that the presence of pathogenic CD8+ T cells does not
affect insulitogenic potential of CD4+ T cells (Figure S4). Interest-
ingly, it appeared that although AI4 CD8+ T cells did not affect
CD4+ T cell accumulation, insulitogenic Phogrin18 CD4+ T cells
did affect AI4 CD8+ T cell islet accumulation.
We also assessed whether the presence of additional islet-
antigen-specific T cell populations in double retrogenic mice
would increase the rate of diabetes incidence compared to 4.1
TCR single retrogenic mice because of alteration of the inflam-
matory milieu. The addition of insulitogenic 12-4.4V1 T cells or
noninsulitogenic 10.23 T cells had no effect on the onset of dia-
betes induced by 4.1 T cells (Figure 5C). Taken together, these
data indicate that diabetogenic CD4+ or CD8+ T cells are unable
to induce further recruitment of and insultis by insulitogenic,
autoantigen-specific CD4+ T cells.648 Immunity 31, 643–653, October 16, 2009 ª2009 Elsevier Inc.A Heterogeneous NOD Diabetogenic T Cell Population
Decreases 12-4.4V1 T Cell Islet Accumulation
Finally, we investigated whether a mixed population of whole
NOD splenocytes would allow greater accumulation of the 12-
4.4V1 T cells that can accumulate in the islets on their own.
Two weeks after bone marrow transplant, we adoptively trans-
ferred 107 whole NOD splenocytes into some of the 12-4.4V1
retrogenic mice to act as a diabetogenic population, and we
analyzed the mice at 4.5–6.5 weeks after bone marrow reconsti-
tution. The numbers of both T cell populations (retrogenic and
NOD wild-type) were comparable to those seen in previous
experiments (Figures 1D and 5B). The presence of NOD T cells
did not seem to have a major effect on the number of retrogenic
T cells in the spleen and PLN (Figure 5E). Surprisingly, the
presence of NOD cells actually reduced the number of retrogenic
12-4.4V1 T cells accumulating in the islets, suggesting that regu-
latory T cells in the NOD population may be influencing the infil-
tration of these autoantigen-specific T cells or that the NOD
T cells are competing for nutrients, space, etc., and thus block
T cell islet entry (Figure 5E). Either way our data clearly show
that diabetogenic T cells cannot facilitate or enhance the entry
or retention of nondiabetogenic T cells.
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Figure 5. An Autoantigen-Specific CD4+ T Cell that Accumulates in the Islet but Does Not Cause Destruction and Does Not Accumulate in
Higher Numbers in the Presence of a Diabetogenic CD4+ T Cell or T Cells from Whole NOD Splenocytes
Retrogenic mice, with diabetogenic 4.1 T cells labeled with YFP and 12-4.4V1 insulin-specific T cells labeled with GFP, were analyzed 4.5–6.5 weeks after trans-
plant.
(A) Representative flow cytometric dot plots from (B), showing 4.1 (YFP) and 12-4.4V1 (GFP) T cells in the spleen and pancreatic islets. Plots are gated on live cells
and CD4+ cells.
(B) Top: percentage of stem cells for each T cell in the bone marrow (n = 7–8), as measured by percentage GFP/YFP expression on LineageSca-1+c-kit+ cells and
total numbers of T cells in the spleen. Next three panels show numbers and ratio to the numbers in the spleen for the pancreatic islets (Islets), inguinal lymph nodes
(I.L.N.), and pancreatic lymph nodes (P.L.N.), respectively (n = 6–9). All figures show mean (±SEM) and numbers were calculated from cell counts and the
percentage CD4+FP+ live cells.
(C) Diabetes incidence.
(D) Representative flow cytometric dot plots from (E), showing analysis of T cells from 12-4.4V1 Insulin-specific mice, injected with 10 3 106 whole splenocytes
from 13-week-old NOD mice, 2 weeks after bone marrow engraftment, and analyzed 4.5–6.5 weeks after transplant. Plots are gated on live cells and CD4+ cells.
(E) Left: percentage of stem cells for each T cell in the bone marrow (n = 7–10), as measured by percentage GFP expression on LineageSca-1+c-kit+ cells and
total numbers of T cells in the spleen. Right panels show the numbers and ratio to the numbers in the spleen for the pancreatic islets (ISLETS) and pancreatic
lymph nodes (P.L.N.), respectively (n = 5–9). All figures show mean (±SEM) and numbers were calculated from cell counts and the percentage CD4+GFP+Vb+
live cells for the retrogenic T cells and the percentage CD4+GFPTCR+ live cells for the NOD T cells.Immunity 31, 643–653, October 16, 2009 ª2009 Elsevier Inc. 649
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Control of T Cell Islet AccumulationInsulitogenic Potential Is Restricted to TCRs Isolated
from Islet-Infiltrating CD4+ T Cells
Our data suggest that the ability of T cells to accumulate in the
islets is cell intrinsic and that T cells that are not specific for an
antigen, which is expressed in the islets and processed and pre-
sented in the PLN, fail to accumulate. It would therefore follow
that the majority of T cells in the islets have accumulated there
based on these criteria. One caveat of our approach is that we
are assessing the insulitogenic potential of specific T cell popula-
tions when present at high precursor frequency, in contrast to
what would be found in unmanipulated NOD mice. To mitigate
this issue, we reasoned that if T cell accumulation and entry is
cell autonomous, then most TCRs isolated from CD4+ T cells puri-
fied from islets and expressed in naive T cells should be able to
mediate islet infiltration, whereas none (or very few) of the TCRs
isolated from splenic CD4+ T cells should be able to do so.
To test this hypothesis, we cloned paired TCR-a and TCR-b
chains from multiple single CD4+ T cells, isolated from either
the islets or spleen of a 13-week-old NOD mouse. To facilitate
cloning, we performed a single cell sort based on Va2 and Vb6
or Vb10 expression and used corresponding primers to clone
Vb and Va chains. The Va2 gene family and the Vb6 and Vb10
gene segments were chosen because of their relatively high
percentage expression in the NOD pancreas and spleen, the
high mean fluorescence intensity of the antibody staining, and
the presence of unique restriction sites in the coding segments
that could be used to facilitate cloning (Figure S5). Our analysis
was limited to four Va2 and two Vb chains, and, therefore, the
TCRs cloned are only partially representative of the infiltrating
CD4+ T cell population. The percentage of Va2+/Vb6+ and
Va2+/Vb10+ T cells in the islets and spleen appeared comparable
(data not shown). We successfully cloned a total of 17 unique in-
frame sequences (12 islet and 5 splenic) (Figure S5, Tables S2
and S3). Two islet-derived clones, GL24.6I1 and GL25.10I1,
were isolated from multiple cells (4 and 14 times, respectively),
which likely reflects the in situ proliferation of these clones. We
did not obtain any repeated sequences in the spleen sample,
nor were any common TCR sequences found between the
spleen and islet samples. Given this relatively small sample
size, compared with the number of infiltrating T cells, it is not
possible to draw definitive conclusions from TCR Ja, Jb, and
CDR3 usage (Table S3). However, usage did not appear obvi-
ously skewed.
We then generated retrogenic NOD-SCID mice expressing
the 17 unique TCRs. Splenic and islet-infiltrating T cells were
analyzed 8–10 weeks after bone marrow reconstitution. As ex-
pected, the capacity of T cell reconstitution varied among the
TCRs, which is likely due to a variety of factors such as the
efficiency of TCR expression and TCR-ab pairing, the influence
of positive and negative selection, and peripheral tolerance.
However, it is noteworthy that T cell reconstitution efficiency is
clearly an inherent characteristic of each TCR, rather than result-
ing from the technique and/or random retroviral integration,
because the error was relatively low within each group.
As anticipated, none of the splenic T cell-derived TCRs medi-
ated T cell islet accumulation to any substantial degree by 8–10
weeks, consistent with the aforementioned hypothesis (Figure 6).
In contrast, 8 of the 12 (67%) islet-derived TCRs mediated some
degree of T cell accumulation in the islets. Four of these (33%)
650 Immunity 31, 643–653, October 16, 2009 ª2009 Elsevier Inc.caused varying degrees of diabetes within the 8–10 week
window of analysis (GL24.6I1, GL24.6I6, GL25.6I9, GL25.10I1)
(Figure 6; Table S3). 10I1 mice were hyperdiabetogenic, as
shown by the fact that most developed diabetes by 5–6 weeks
postreconstitution, and thus were analyzed when they became
diabetic rather than at 8 weeks. Curiously, another TCR,
GL25.6I9, caused diabetes at 10 weeks in some mice, but
produced no substantial accumulation in the remaining mice.
The remaining four islet-derived T cells, GL28.6I16, GL28.6I26,
GL25.6I36, and GL23.10I35, showed minimal to no accumula-
tion at 8–10 weeks postengraftment. However, it is possible
that this may be too early for some TCRs or T cells, as indicated
by the fact that several previously characterized insulitogenic-
diabetogenic TCRs mediate minimal insulitis (e.g., Phogrin18)
and minimal diabetes incidence (e.g., 12-4.1 and BDC6.9) at
10 weeks posttransfer (Burton et al., 2008). It is also possible
that some of the cellular infiltrate may have resolved by 10
weeks. If one considers the duplicated TCRs that were indepen-
dently isolated from single islet-infiltrating T cells, these data
suggest that an even higher percentage of these T cells (86%;
24 of 28 islet-isolated clones) are able to cell autonomously
mediate islet accumulation and/or induce diabetes, whereas
none of the spleen-derived TCRs are able to do so.
DISCUSSION
There is a pervasive notion that the majority of infiltrating T cells
at the site of autoimmune destruction are not specific for islet
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Figure 6. TCRs Isolated from NOD Islets-Infiltrating CD4+ T Cells
Can Mediate T Cell Accumulation in the Islets of Retrogenic Mice
Va2+Vb6+ and Va2+Vb10+ CD4+ T cells were single-cell sorted from the spleen
and islets of a 13-week-old female NOD mouse. The TCR chains were then
amplified with a nested RT-PCR, sequenced, and cloned into a 2A-linked
retroviral vector. Retrogenic mice generated with these vectors were analyzed
8–10 weeks after engraftment (n = 2–11). Shown are numbers of CD4+GFP+
T cells in the spleen (top) and pancreatic islets (bottom). Plots are gated on
live cells. Islet-derived clones are indicated by the black bars and the ‘‘I’’ in
their name, splenic clones by open bars and the ‘‘S’’ in their name. NY4.1 is
included as a control and is indicated by the gray bar. The asterisk indicates
that mice in this group were diabetic when analyzed at 8–10 weeks after
engraftment. GL25.10I1 T cells induced rapid diabetes, and these mice were
analyzed at 5–6 weeks after engraftment.
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Control of T Cell Islet Accumulationantigens and have been recruited via a cell-extrinsic mechanism.
However, there is little direct support for this, with most of the
current data being circumstantial (Peterson et al., 1998; Wen
et al., 1998; Rhode et al., 2005; Carvalho-Pinto et al., 2004).
Our data suggest that this assumption may be incorrect. Despite
the presence of substantial insulitis mediated by diabetogenic
T cells in double TCR retrogenic mice, no additional population
was enticed nor could be directed to enter and be retained in
the islets. Importantly, six different TCRs, which display a spec-
trum of insulitogenic potential, were used, indicating that this is
not a deciding factor in whether diabetogenic T cells can mediate
islet entry and accumulation of a third party T cell population.
Four distinct diabetogenic T cell populations (4.1 and BDC2.5
CD4+ retrogenic T cells, AI-4 CD8+ retrogenic T cells, and hetero-
geneous NOD T cells) were unable to facilitate third party T cell
islet entry or retention, reducing the possibility that these obser-
vations were due to a limitation in our approach or a unique
characteristic of certain diabetogenic T cell populations. Finally,
we cloned the TCR-ab chain pairs from 12 unique CD4+ T cells
isolated by single-cell sorting from the islets of a NOD mouse
and demonstrated that 8 of these (67%) could mediate T cell islet
accumulation and/or induce diabetes in mice. Given that 2 of
the cloned TCRs were isolated from 18 T cells, this may actually
represent a higher percentage of in vivo population. A parallel
sample of TCRs isolated from five splenic single cell cloned
CD4+ T cells of the same mouse failed to mediate T cell
islet accumulation to any significant degree. Taken together,
our data suggest that inflammation induced by diabetogenic
CD4+ T cells alone may not be sufficient to mediate third
party or bystander CD4+ T cell islet entry and/or retention and
further suggests that islet accumulation is a cell-autonomous
event.
Our data also confirm that islet antigen expression is a key
factor in determining the ability of a given T cell population to
accumulate in the islets, because GAD-specific T cells could
accumulate only when GAD was expressed in the islets. This
finding correlates well with findings from a previous study, where
MHC class I expression is inhibited in the pancreatic b cells of
NOD mice by expression of a RIP-E19 transgene, resulting in
a reduced accumulation of CD8+ T cells in the islets (Yamanou-
chi et al., 2003). However, another study found that conditional
deletion of MHC class I on b cells does not affect infiltration
but instead reduces the incidence of diabetes and delayed onset
(Hamilton-Williams et al., 2003).
An important benefit of the TCR retrogenic system used here is
the fact that one has complete control over the T cell populations
present in the mice and thus the ability to track, manipulate, and
isolate these T cell populations for further analysis. One caveat,
however, is that these analyses were not performed at physio-
logical T cell densities in vivo. It could be argued that this
may change the ‘‘rules’’ that govern the processes that control
T cell islet accumulation, which might be more complex than
recapitulated here. Alternatively, it could be argued that the dia-
betogenic T cell density may in fact be far higher in this setting
and thus a ‘‘sterner test’’ of whether islet accumulation is really
cell autonomous. Regardless, our data are consistent with the
notion that T cell islet accumulation is autoantigen specific and
cell autonomous, and suggest that further analyses of these
processes are warranted.Most of the work that supports bystander recruitment used
adoptive transfer studies that may result in an artificially high or
robust response. Previous work suggests that adoptive transfer
of BDC2.5 T cells into NOD mice induces islet destruction that
facilitates the recruitment of a large diverse T cell population,
most of which does not appear to be highly activated based
on CD25 expression and response to IL-2 (Peterson et al.,
1998). It is assumed that these cells are not autoantigen specific
and that the inflammatory environment is responsible for their
recruitment and entry into the pancreatic islets. However, this
is not directly demonstrated. Another transfer study used
BDC2.5 T cells and DO11 T cells, which recognize OVA peptide
presented on H-2Ad molecules, injected into NOD-SCID 3
CB17-SCID F1 mice, which expressed both H-2Ad and H-2Ag7.
Injection of mice with OVA peptide prevents diabetes, although
it has no effect on infiltration (Suri et al., 2004). Because both
T cell populations can be detected in the pancreas, it was sug-
gested that the activated DO11 T cells, which do not recognize
an islet antigen, can enter the islets when BDC2.5 was present
(Suri et al., 2004). However, the timing of the injection is critical
and it is possible that soluble OVA peptide could be presented
by APCs in the islets because of damage caused by the pres-
ence of the BDC2.5 cells, or that the number of diabetogenic
T cells is unphysiological. The use of transgenic mice that
express the OVA peptide at another location might exclude
this possibility. Lastly, expression of the chemokine CXCL10 in
the b cells of the pancreas, via a RIP-transgene, leads to peri-
insulitis and some impairment of b cell function, but no diabetes
(Rhode et al., 2005). The mice used in the study were on
a C57BL/6 background and do not spontaneously develop dia-
betes. This would therefore appear to indicate that the expres-
sion of molecules involved in inflammatory responses can influ-
ence the trafficking of T cells to the islets, regardless of their
ability to cause disease. The only known ligand for CXCL10,
CXCR3, is upregulated on activated T cells, but only Th1 cells
show CXCR3-mediated trafficking in response to inflammation
(Xie et al., 2003), which could explain the bias seen in NOD
mice. Indeed, neutralization of CXCL10 reduces the incidence
of diabetes in NOD mice after cyclophosphamide administration
(Morimoto et al., 2004). Also, infection with a virus that expands
in the pancreatic lymph nodes abrogates diabetes in both
a virus-induced model of diabetes and NOD mice, apparently
by attracting T cells from the islets with high CXCL10 concentra-
tions (Christen et al., 2004). It is therefore tempting to speculate
that the ability of T cells to enter and accumulate in the islets is
due to antigenic activation, leading to expression of CXCR3.
Overall, our data show that the ability of T cells to infiltrate or
accumulate in the pancreatic islets is cell autonomous, antigen
specific, and tightly regulated. However, our data also raise the
intriguing and potentially important possibility that the majority
of the T cells in the pancreatic islets are autoantigen specific.
Indeed, there is evidence that up to 40% of CD8+ T cells infil-
trating the islets of NOD mice are responsive to the islet antigen
IGRP (Han et al., 2005) and inhibiting MHC class I expression on
b cells has been shown to impair CD8+ T cell accumulation in the
islets (Yamanouchi et al., 2003). When we directly ‘‘sampled’’ the
pancreas to determine the cell-autonomous insulitogenic poten-
tial of islet-infiltrating T cells through single-cell cloning and re-
expression in retrogenic mice, 67% of the unique islet-derivedImmunity 31, 643–653, October 16, 2009 ª2009 Elsevier Inc. 651
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Control of T Cell Islet AccumulationTCRs mediated accumulation or caused diabetes. However, one
should note that only a proportion of the islet-infiltrating CD4+
T cell population (Va2/Vb6+; Va2/Vb10+) was sampled and thus
additional studies will be required to determine whether these
observations can be extrapolated. Nevertheless, these findings
increase the value of direct analysis of islet-infiltrating T cells.
Whether this finding relates in any way to other autoimmune
diseases remains to be determined. Indeed, some have sug-
gested that the majority of the T cells in arthritic joints are not
autoantigen specific (Cantagrel et al., 1998). It is possible that
the structure, location, and chemokine expression of the pancre-
atic islet in NOD mice makes it uniquely inaccessible to nonau-
toantigen-specific T cells. However, it is possible that the observa-
tions made here may apply to other organ-specific autoimmune
diseases. Either way, our study raises important questions about
the T cell clonality and specificity in autoimmune foci and
suggests that additional analysis is warranted. In conclusion,
our findings suggest that the T cell islet entry is cell autonomous
and that TCR specificity for islet antigens is the key factor that
determines islet entry. This raises three important issues. First,
our data suggest that all the T cells in islets are islet antigen
specific. Second, our data suggest that the inhibition of islet
entry/retention may have a more significant therapeutic benefit
than previously appreciated. Third, our data further support the
potential therapeutic validity of antigen-specific modalities in
the treatment of type 1 diabetes.
EXPERIMENTAL PROCEDURES
Mice
NOD-SCID and NOD.Cg-Prkdcscid Tg(Ins2-GAD2)2Lt/LtJ mice were obtained
from Jackson Laboratories and were bred in the St. Jude Animal Resources
Center (Memphis, TN). All animal experiments were preformed in an AAA-
LAC-accredited, SPF facility according to national, state, and institutional
guidelines. Animal protocols were approved by the St. Jude Institutional
Animal Care and Use Committee.
TCR Reagents and Retroviral-Mediated Stem Cell Gene Transfer
All retroviral TCR constructs used in this paper are listed in Tables S1 and S3
and have been described previously (Arnold et al., 2004; Burton et al., 2008)
with the exception of AI4 (a gift from T. DiLorenzo, Albert Einstein College of
Medicine, and D. Serreze, The Jackson Laboratory) and those cloned from
single cells (GL series; see below).
Retroviral transduction of murine bone marrow cells was performed as
previously described (Szymczak et al., 2004; Holst et al., 2006a). In brief,
female NOD/SCID bone marrow was cultured for 48 hr in complete DMEM
supplemented with 20% FBS, 20 ng/ml IL-3, 50 ng/ml IL-6, and 50 ng/ml
stem cell factor (BioSource, Carlsbad, CA). Bone marrow cells were then har-
vested and cocultured with irradiated retroviral producer cell lines for an addi-
tional 48 hr. The transduced bone marrow cells were then washed off the retro-
viral cells and combined, so that mice receiving 50:50 mixes received equal
numbers of each type of bone marrow, and so that different groups received
the same total number of cells, with single retrogenic controls receiving half
that number (>4 3 106 total BM cells). The cells were then washed, resus-
pended in PBS/2% FBS with 20 U/ml heparin, and injected via the tail vein
into sublethally irradiated mice (300 rads). Mice were test-bled for TCR recon-
stitution 4 weeks after transplant and analyzed 4.5–6.5 weeks after transplant.
Flow Cytometric Analysis of Bone Marrow Recipient Mice
Bone marrow, spleens, inguinal lymph nodes (ILN), pancreatic lymph nodes
(PLN), and pancreatic islets were removed, processed, counted, stained,
and then analyzed on a LSRII flow cytometer (BD PharMingen, San Diego,
CA). For the bone marrow, cells were stained with anti-Sca-1-biotin, followed
by anti-c-kit-APC, anti-CD3e-PE, anti-B220-PE, anti-Gr-1-PE, anti-Mac-1-PE,652 Immunity 31, 643–653, October 16, 2009 ª2009 Elsevier Inc.anti-TER-119-PE, and streptavidin-PE-Cy5. Cells were gated on Linea-
geSca-1+c-kit+ (PElo, PECy5hi, APChi), and the percentage of GFP+ and
YFP+ stem cells determined from a dot plot. For the lymphocytes from the
other organs, cells were stained with anti-CD69-PE, anti-CD25-PE-Cy5, and
anti-CD4-AlexaFluor647 or with anti-CD44-PE, anti-CD25-Cy5, anti-CD62L-
APC (eBioscience, San Diego, CA), and anti-CD4-APC-Cy7. When staining
with Vb-specific antibodies, cells were stained first with anti-Vb6-biotin, anti-
Vb12-biotin, or anti-Vb8.1-biotin, followed by anti-Vb11-PE, anti-CD25-PE-
Cy5, anti-CD4-APC-Cy7, and streptavidin-APC. For staining of T cells from
AI-4 Rg mice, anti-CD8-PE was used. Cells were resuspended in DAPI imme-
diately prior to analysis. The unused PE-texas red channel on the LSRII was
compensated and used to gate-out auto-fluorescent cells during data anal-
ysis. All antibodies were from BD PharMingen unless stated otherwise.
Recovery of T Cells from the Pancreatic Islets
T cells were isolated from the islets as described previously (Burton et al.,
2008). In brief, the pancreas was flushed with 3 ml of collagenase type P
(Roche Diagnostics, Indianapolis, IN), excised, and incubated for 37C for
15–20 min in 4 ml of collagenase. The pancreata were then disrupted and
washed twice with DMEM or RPMI, +10% FBS. The islets were picked under
a dissecting microscope with a P10 pipette, disrupted by the addition of 1 ml of
cell dissociation buffer (GIBCO, Grand Island, NY), 15 min incubation at 37C
and vortexing. After another wash, the cells were resuspended, counted, and
used.
Cloning of TCRs from T Cells Isolated by Single-Cell Sorting
Cells were prepared from the islets and spleen of a 13-week-old female NOD/
Ltj mouse and stained with anti-CD4-PE-Cy7, anti-Va2-FITC, anti-Vb10-PE,
and anti-Vb6-biotin, then streptavidin-APC (all antibodies BD PharMingen).
Va2+Vb6+CD4+ and Va2+Vb10+CD4+ T cells were then single-cell sorted into
the wells of 96-well PCR plates with the Cyclone attachment on a Mo-Flo
cell sorter (Beckman-Coulter, Fullerton, CA). Plates were stored frozen at
80C until needed. Two-round PCR method modified from Kedzierska
et al. (2004) was used to amplify the Va and Vb chains (see Supplemental
Experimental Procedures for more details).
Diabetes Monitoring
Diabetes onset was monitored by urine analysis with Clinistix (Bayer Corpora-
tion, Elkhart, IN) and confirmed by a blood glucose measurement of more than
400 mg/dl or more than 200 mg/dl for two consecutive measurements, via
a One Touch Ultra glucometer (LifeScan, Milpitas, CA).
Statistical Analysis
The differences in numbers of T cells between groups was calculated by
one-tailed t test, via the statistical analysis function of GraphPad Prism 4.03
(GraphPad Software Inc, San Diego, CA).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, five
figures, and three tables and can be found with this article online at http://
www.cell.com/immunity/supplemental/S1074-7613(09)00410-5.
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